Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention

Thrombosis Research

Volumn 119, Issue 4, 2007, Pages 453-459

  Ozdol, Cagdas ^a   Gulec, Sadi ^a   Rahimov, Uzeyir ^a   Atmaca, Yusuf ^a   Turhan, Sibel ^a   Erol, Cetin ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Inflammation; Myonecrosis; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CONTRAST MEDIUM; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NAPROXEN; NITRATE; TROPONIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; CREATINE KINASE BLOOD LEVEL; DEATH; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCLE NECROSIS; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE INFLAMMATION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SURVIVAL TIME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; C-REACTIVE PROTEIN; CREATINE KINASE, MB FORM; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; INTRAOPERATIVE PERIOD; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NAPROXEN; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; TROPONIN I;

EID: 33846461166     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.11.003     Document Type: Article

References (33)

1. Fuchs S., Kornowski R., Mehran R., Lansky A.J., Satler L.F., Pichard A.D., et al. Prognostic value of cardiac troponin-1 levels following catheter-based coronary interventions. Am J Cardiol 85 (2000) 1077-1082
2. Simoons M.L., Brand M., Lincoff M., Harrington R., van der Wieken R., Vahanian A., et al. Minimal myocardial damage during coronary intervention is associated with impaired outcome. Eur Heart J 20 (1999) 1112-1119
3. Abdelmeguid A.E., Topol E.J., Whitlow P.L., Sapp S.K., and Ellis S.G. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 94 (1996) 1528-1536
4. Akkerhuis K.M., Alexander J.H., Tardiff B.E., Boersma E., Harrington R.A., Lincoff A.M., et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?. Circulation 105 (2002) 554-556
5. Ellis S.G., Chew D., Chan A., Whitlow P.L., Schneider J.P., and Topol E.J. Death following creatine kinase-MB elevation after coronary intervention. Circulation 106 (2002) 1205-1210
6. Azar R.R., McKay R.G., Kiernan F.J., Seecharran B., Feng Y.J., Fram D.B., et al. Coronary angioplasty induces a systemic inflammatory response. Am J Cardiol 80 (1997) 1476-1478
7. Gaspardone A., Crea F., Versaci F., Tomai F., Pellegrino A., Chiariello L., et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 82 (1998) 515-518
8. Versaci F., Gaspardone A., Tomai F., Crea F., Chiariello L., and Gioffre P.A. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol 85 (2000) 92-95
9. Lincoff A.M., Kereiakes D.J., Mascelli M.A., Deckelbaum L.I., Barnathan E.S., Patel K.K., et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 104 (2001) 163-167
10. Liuzzo G., Buffon A., Biasucci L.M., Gallimore J.R., Caligiuri G., Vitelli A., et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 98 (1998) 2370-2376
11. Gottsauner-Wolf M., Zasmeta G., Hornykewycz S., Nikfardjam M., Stepan E., Wexberg P., et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 21 (2000) 1152-1158
12. Chew D.P., Bhatt D.L., Robbins M.A., Penn M.S., Schneider J.P., Lauer M.S., et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 104 (2001) 992-997
13. Dibra A., Mehilli J., Braun S., Hadamitzky M., Baum H., Dirschinger J., et al. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am Heart J 150 (2005) 344-350
14. Chew D.P., Bhatt D.L., Robbins M.A., Mukherjee D., Roffi M., Schneider J.P., et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 88 (2001) 672-674
15. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330 (1994) 956-961
16. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336 (1997) 1689-1696
17. The EPISTENT Investigators. Randomised, placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein IIb/IIIa blockade. Lancet 352 (1998) 87-92
18. Herrmann J., Lerman A., Baumgart D., Volbracht L., Schulz R., von Birgelen C., et al. Pre-procedural statin medication reduces the extent of peri-procedural non-Q-wave myocardial infarction. Circulation 106 (2002) 2180-2183
19. Aronow H.D., Quinn M.J., Gurm H.S., Topol EJ., Lincoff M., Brennan DM., et al. Myocardial necrosis is halved in patients undergoing elective percutaneous coronary intervention who are pretreated with lipid lowering therapy. J Am Coll Cardiol 39 (2002) 32A [Abstract]
20. Strauss B.H., Escaned J., Foley D.P., di Mario C., Haase J., Keane D., et al. Quantitative coronary angiography (QCA) in interventional cardiology: clinical application of QCA measurements. Prog Cardiovasc Dis 36 (1994) 363-384
21. Ellis S.G., Vandormael M.G., Cowley M.J., and the POSCH Group. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation 82 (1990) 1193-1202
22. Inoue T., Kato T., Uchida T., Sakuma M., Nakajima A., Shibazaki M., et al. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol 46 (2005) 239-245
23. Serrano C.V., Ramires J.A.F., Venturinelli M., Arie S., D'Amico E., Zweier J.L., et al. Coronary angioplasty results in leucocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol 29 (1997) 1276-1283
24. Blum A., Sclarovsky S., and Shohat B. T lymphocytes activation in stable angina pectoris and after percutaneous transluminal coronary angioplasty. Circulation 91 (1995) 20-22
25. Almagor M., Keren A., and Banai S. Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. Am Heart J 145 (2003) 248-253
26. Vivekananthan D.P., Bhatt D.L., Chew D.P., Zidar F.J., Chan A.W., Moliterno D.J., et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 94 (2004) 358-360
27. Gaspardone A., Versaci F., Proietti I., Tomai F., Altamura L., Skossyreva O., et al. Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and six-month clinical events. Am J Cardiol 90 (Oct 1 2002) 786-789
28. Guler N., Batyraliev T., Dulger H., Ozkara C., Tuncer M., Aslan S., et al. The effects of short term (3 weeks) testosterone treatment on serum inflammatory markers in men undergoing coronary artery stenting. Int J Cardiol 109 (2006) 339-343
29. Saadeddin S.M., Habbab M.A., Sobki S.H., and Ferns G.A. Association of systemic inflammatory state with troponin I elevation after elective uncomplicated percutaneous coronary intervention. Am J Cardiol 89 (Apr 15 2002) 981-983
30. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., Tournier B., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001) 1809-1817
31. MacDonald T.M., and Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361 (2003) 573-574
32. Loll P.J., Picot D., and Garavito R.M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 2 (1995) 637-643
33. National Institute of Health, NIH Office of Communications and Public Liaison. Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer′s disease prevention trial. Available at: http://www.nih.gov/news/or/dec2004/od-20.htm. Accessed April 12, 2005.